These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

974 related items for PubMed ID: 28318150

  • 1. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [Abstract] [Full Text] [Related]

  • 2. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [Abstract] [Full Text] [Related]

  • 3. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE.
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H.
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [Abstract] [Full Text] [Related]

  • 5. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM.
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [Abstract] [Full Text] [Related]

  • 6. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [Abstract] [Full Text] [Related]

  • 7. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, Kim DD, Thyagu S, Messner HA, Michelis FV.
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [Abstract] [Full Text] [Related]

  • 8. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Tiribelli M, Raspadori D, Geromin A, Cavallin M, Sirianni S, Simeone E, Bocchia M, Fanin R, Damiani D.
    Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
    [Abstract] [Full Text] [Related]

  • 9. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM.
    Cancer; 2012 Dec 15; 118(24):6110-7. PubMed ID: 22736495
    [Abstract] [Full Text] [Related]

  • 10. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M.
    Turk J Haematol; 2017 Dec 01; 34(4):300-306. PubMed ID: 28294102
    [Abstract] [Full Text] [Related]

  • 11. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B Study.
    J Clin Oncol; 2007 Aug 01; 25(22):3337-43. PubMed ID: 17577018
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.
    Eur J Haematol; 2008 Mar 01; 80(3):208-15. PubMed ID: 18081718
    [Abstract] [Full Text] [Related]

  • 13. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H, Li XQ, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP, Han Y.
    J Cancer Res Clin Oncol; 2021 Sep 01; 147(9):2659-2670. PubMed ID: 33550446
    [Abstract] [Full Text] [Related]

  • 14. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM, Ebid GT, Madney YM, Abo-Elazm OM, Kelany AK, Torra OS, Radich JP.
    Clin Lymphoma Myeloma Leuk; 2019 Jun 01; 19(6):e281-e290. PubMed ID: 30926392
    [Abstract] [Full Text] [Related]

  • 15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS, Hu YL, Guan LX, Peng B, Wang SY.
    Hematology; 2021 Dec 01; 26(1):179-185. PubMed ID: 33594943
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L.
    Ann Hematol; 2014 Aug 01; 93(8):1279-86. PubMed ID: 24801015
    [Abstract] [Full Text] [Related]

  • 17. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K.
    Ann Hematol; 2012 Jan 01; 91(1):9-18. PubMed ID: 21744003
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G, Study Alliance Leukemia.
    Biol Blood Marrow Transplant; 2016 Mar 01; 22(3):462-9. PubMed ID: 26551637
    [Abstract] [Full Text] [Related]

  • 19. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, Teshima T, Shimoda K, Akashi K, Harada M.
    Eur J Haematol; 2007 Jul 01; 79(1):17-24. PubMed ID: 17598835
    [Abstract] [Full Text] [Related]

  • 20. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP, Yan LZ, Yang L, Chen SN, Wu XJ, Liang JY.
    Zhonghua Nei Ke Za Zhi; 2007 Nov 01; 46(11):907-10. PubMed ID: 18261272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.